vs
EPLUS INC（PLUS）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是EPLUS INC的1.3倍（$772.1M vs $614.8M），Revvity净利率更高（12.7% vs 5.7%，领先7.0%），EPLUS INC同比增速更快（20.3% vs 5.9%），过去两年Revvity的营收复合增速更高（9.0% vs 2.3%）
ePlus Inc.是美国的科技咨询解决方案提供商，业务覆盖网络安全、云计算、网络架构、协作办公、人工智能及前沿技术领域，为超5000家客户提供定制化解决方案、专业咨询与托管服务，助力企业实现数字化转型与技术升级。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
PLUS vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.3倍
$614.8M
营收增速更快
PLUS
高出14.5%
5.9%
净利率更高
RVTY
高出7.0%
5.7%
两年增速更快
RVTY
近两年复合增速
2.3%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $614.8M | $772.1M |
| 净利润 | $35.1M | $98.4M |
| 毛利率 | 25.8% | — |
| 营业利润率 | 7.1% | 14.5% |
| 净利率 | 5.7% | 12.7% |
| 营收同比 | 20.3% | 5.9% |
| 净利润同比 | 45.2% | 3.9% |
| 每股收益（稀释后） | $1.33 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PLUSRVTY
| Q4 25 | $614.8M | $772.1M | ||
| Q3 25 | $608.8M | $698.9M | ||
| Q2 25 | $637.3M | $720.3M | ||
| Q1 25 | — | $664.8M | ||
| Q4 24 | $493.2M | $729.4M | ||
| Q3 24 | $493.4M | $684.0M | ||
| Q2 24 | $535.7M | $691.7M | ||
| Q1 24 | — | $649.9M |
净利润PLUSRVTY
| Q4 25 | $35.1M | $98.4M | ||
| Q3 25 | $34.9M | $46.7M | ||
| Q2 25 | $37.7M | $53.9M | ||
| Q1 25 | — | $42.2M | ||
| Q4 24 | $24.1M | $94.6M | ||
| Q3 24 | $31.3M | $94.4M | ||
| Q2 24 | $27.3M | $55.4M | ||
| Q1 24 | — | $26.0M |
毛利率PLUSRVTY
| Q4 25 | 25.8% | — | ||
| Q3 25 | 26.6% | 53.6% | ||
| Q2 25 | 23.3% | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | 25.4% | — | ||
| Q3 24 | 25.8% | 56.3% | ||
| Q2 24 | 23.7% | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率PLUSRVTY
| Q4 25 | 7.1% | 14.5% | ||
| Q3 25 | 8.0% | 11.7% | ||
| Q2 25 | 5.7% | 12.6% | ||
| Q1 25 | — | 10.9% | ||
| Q4 24 | 3.3% | 16.3% | ||
| Q3 24 | 5.5% | 14.3% | ||
| Q2 24 | 5.9% | 12.4% | ||
| Q1 24 | — | 6.8% |
净利率PLUSRVTY
| Q4 25 | 5.7% | 12.7% | ||
| Q3 25 | 5.7% | 6.7% | ||
| Q2 25 | 5.9% | 7.5% | ||
| Q1 25 | — | 6.4% | ||
| Q4 24 | 4.9% | 13.0% | ||
| Q3 24 | 6.3% | 13.8% | ||
| Q2 24 | 5.1% | 8.0% | ||
| Q1 24 | — | 4.0% |
每股收益（稀释后）PLUSRVTY
| Q4 25 | $1.33 | $0.86 | ||
| Q3 25 | $1.32 | $0.40 | ||
| Q2 25 | $1.43 | $0.46 | ||
| Q1 25 | — | $0.35 | ||
| Q4 24 | $0.91 | $0.77 | ||
| Q3 24 | $1.17 | $0.77 | ||
| Q2 24 | $1.02 | $0.45 | ||
| Q1 24 | — | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $326.3M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.1B | $7.3B |
| 总资产 | $1.8B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PLUSRVTY
| Q4 25 | $326.3M | $919.9M | ||
| Q3 25 | $402.2M | $931.4M | ||
| Q2 25 | $480.2M | $991.8M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | $253.1M | $1.2B | ||
| Q3 24 | $187.5M | $1.2B | ||
| Q2 24 | $349.9M | $2.0B | ||
| Q1 24 | — | $1.7B |
股东权益PLUSRVTY
| Q4 25 | $1.1B | $7.3B | ||
| Q3 25 | $1.0B | $7.4B | ||
| Q2 25 | $1.0B | $7.6B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | $962.3M | $7.7B | ||
| Q3 24 | $947.0M | $7.9B | ||
| Q2 24 | $921.9M | $7.9B | ||
| Q1 24 | — | $7.8B |
总资产PLUSRVTY
| Q4 25 | $1.8B | $12.2B | ||
| Q3 25 | $1.8B | $12.1B | ||
| Q2 25 | $1.8B | $12.4B | ||
| Q1 25 | — | $12.4B | ||
| Q4 24 | $1.8B | $12.4B | ||
| Q3 24 | $1.7B | $12.8B | ||
| Q2 24 | $1.7B | $13.4B | ||
| Q1 24 | — | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-87.4M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | -2.49× | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流PLUSRVTY
| Q4 25 | $-87.4M | $182.0M | ||
| Q3 25 | $-34.8M | $138.5M | ||
| Q2 25 | $-99.0M | $134.3M | ||
| Q1 25 | — | $128.2M | ||
| Q4 24 | $65.7M | $174.2M | ||
| Q3 24 | $-21.6M | $147.9M | ||
| Q2 24 | $97.1M | $158.6M | ||
| Q1 24 | — | $147.6M |
自由现金流PLUSRVTY
| Q4 25 | — | $161.8M | ||
| Q3 25 | — | $120.0M | ||
| Q2 25 | — | $115.5M | ||
| Q1 25 | — | $112.2M | ||
| Q4 24 | — | $149.8M | ||
| Q3 24 | — | $125.6M | ||
| Q2 24 | — | $136.6M | ||
| Q1 24 | — | $129.7M |
自由现金流率PLUSRVTY
| Q4 25 | — | 21.0% | ||
| Q3 25 | — | 17.2% | ||
| Q2 25 | — | 16.0% | ||
| Q1 25 | — | 16.9% | ||
| Q4 24 | — | 20.5% | ||
| Q3 24 | — | 18.4% | ||
| Q2 24 | — | 19.7% | ||
| Q1 24 | — | 20.0% |
资本支出强度PLUSRVTY
| Q4 25 | — | 2.6% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | — | 3.3% | ||
| Q2 24 | — | 3.2% | ||
| Q1 24 | — | 2.7% |
现金转化率PLUSRVTY
| Q4 25 | -2.49× | 1.85× | ||
| Q3 25 | -1.00× | 2.97× | ||
| Q2 25 | -2.63× | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | 2.72× | 1.84× | ||
| Q3 24 | -0.69× | 1.57× | ||
| Q2 24 | 3.55× | 2.87× | ||
| Q1 24 | — | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PLUS
| All Others Customer End Market | $107.0M | 17% |
| Technology Customer End Market | $89.4M | 15% |
| Health Care Customer End Market | $81.5M | 13% |
| Financial Services Customer End Market | $66.1M | 11% |
| Professional Services Reporting Unit | $64.1M | 10% |
| Security | $61.1M | 10% |
| State And Local Government And Educational Institutions | $59.9M | 10% |
| Managed Services Reporting Unit | $48.8M | 8% |
| Other Product | $21.1M | 3% |
| Collaboration | $13.4M | 2% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
